Log In
Print this Print this

ADXS-HER2 (ADXS31-164) (formerly ADXS-cHER2, Lovaxin B)

  Manage Alerts
Collapse Summary General Information
Company Advaxis Inc.
DescriptionLive attenuated Listeria monocytogenes immunotherapy targeting HER2
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today